High-Level Drug-Resistant Mutations among HIV-1 Subtype A6 and CRF02_AG in Kazakhstan

Sanaubarova, A; Pujol-Hodge, Emma; Dzissyuk, Natalya; Lemey, Philippe; Vermund, Sten H.; Brown, Andrew; Ali, Syed

doi:10.3390/v15071407

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This discrepancy may be because most of the viruses in our study belonged to sub‐subtype A6. Previous studies have indicated a disproportionate prevalence of NNRTI DRMs in the A6 sub‐subtype compared with the CRF_02AG subtype [14, 31]. In this subtype, the substitution of a single nucleotide in position 190 can result in the replacement of glycine (G) with serine (S), whereas, in other subtypes, it necessitates a change of two nucleotides [32].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia

Ozhmegova,

Lebedev,

Antonova

et al. 2024

HIV Medicine

View full text Add to dashboard Cite

BackgroundThis study aimed to investigate mutations associated with, the causes of, and the conditions that contribute to HIV drug resistance (DR). This research provides crucial insights into the mechanisms through which HIV evades antiretroviral drugs and suggests strategies to counter this phenomenon. Our objective was to assess the prevalence and structure of DR in HIV‐1 across various regions in Russia and identify the primary factors influencing the development of HIV DR.MethodsThe study used nucleotide sequences from the HIV‐1 pol gene obtained from 1369 patients with a history of therapy and virological failure between 2005 and 2019 to analyze the frequency and structure of DR and the factors associated with it.ResultsThe analysed HIV‐1 genotypes included viruses resistant to nucleoside reverse transcriptase inhibitors (NRTIs; 11.8%), non‐nucleoside reverse transcriptase inhibitors (NNRTIs; 6.4%), and NRTIs + NNRTIs (31.7%). The mutations M184V/I and G190A/S/E were the most prevalent, accounting for 54.5% and 26.6%, respectively. The dominance of multiple DR persisted throughout the entire observation period. The likelihood of encountering drug‐resistant variants was increased among men, patients in the late stage of infection, and those with a viral load <30 000 RNA copies/mL. Injection drug use was not associated with DR.ConclusionThis study has yielded new insights into HIV DR in Russia, offering valuable information to identify clinical or programmatic events warranting closer attention and support.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia

Ozhmegova,

Lebedev,

Antonova

et al. 2024

HIV Medicine

View full text Add to dashboard Cite

show abstract

“…The presence of K103N is primary conditioned by the use of EFV as part of the preferred first-line therapy regimen in Russia [48]. In previous studies, the predominance of K103N among naїve patients infected with CRF63_02A6 and CRF02_AG was noted [49,50].…”

Section: Discussionmentioning

confidence: 99%

Recombinant Forms of HIV-1 in the Last Decade of the Epidemic in the Russian Federation

Antonova,

Kazennova,

Lebedev

et al. 2023

Viruses

View full text Add to dashboard Cite

Currently, HIV-1 displays a substantial level of genetic diversity on a global scale, partly attributed to its recombinant variants. This study seeks to identify and analyze HIV-1 recombinants in Russia during the last decade of the epidemic. A comprehensive examination was conducted, encompassing 3178 partial pol sequences. Subtyping was achieved through various programs including COMET, the Stanford Database, REGA, jpHMM, RIP, and RDP4 for recombination analysis. The study also involved phylogenetic analysis to trace the origins of the identified recombinants. Primary resistance (PrimDR) prevalence and Drug Resistance Mutations (DRMs) were assessed. The study uncovered an overall proportion of recombinants at 8.7%, with a statistically significant increase in their frequency observed over time (p < 0.001). The Northwestern (18.5%) and Siberian (15.0%) Federal Districts exhibited a high prevalence of recombinants, while the Volga (1.9%) and Ural (2.8%) Federal Districts had a lower prevalence. Among HIV-1 recombinants, a PrimDR prevalence of 11.4% was identified. Notably, significant differences in DRMs were observed, with a higher prevalence of M184V in sub-subtype A6 (p = 0.018) and K103N in CRF63_02A6 (p = 0.002). These findings underscore the increasing HIV-1 genetic diversity and highlight a substantial prevalence of PrimDR among its recombinant forms, emphasizing the necessity for ongoing systematic monitoring.

show abstract

Genetic Diversity and Drug Resistance Mutations in HIV-1 pol Gene Sequences in the Philippines: A Retrospective Genomic Analysis

Reyes,

Tolentino,

Castillo

et al. 2024

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

The Philippines has experienced a significant increase in HIV-1 infections in recent years, with a growing epidemic driven by the CRF01_AE strain. Understanding the genetic diversity of HIV-1 in the Philippines is crucial for the development of effective treatment strategies and the prevention of drug resistance. This study analyzed comprehensive data on common resistance mutation patterns from 2009 to 2017, revealing an increasing trend of mutations observed in NRTI and NNRTI resistance among the predominant CRF01_AE strains. The most common NRTI mutations observed were M184V, K65R, and S68G, whereas the most common NNRTI mutations were K103N, Y181C, and G190A. The study also found a high prevalence of M184V minority variants (0.5-20%) in treatment-naive patients, which could increase the risk of virological failure in 3TC-containing regimens. The findings of this study highlight the importance of comprehensive drug resistance surveillance and access to resistance testing to guide optimal first-line antiretroviral treatment selection and to manage the growing HIV-1 epidemic in the Philippines. The development of effective strategies to prevent and manage drug resistance is crucial to ensuring the long-term success of HIV treatment programs in the country.

show abstract

High-Level Drug-Resistant Mutations among HIV-1 Subtype A6 and CRF02_AG in Kazakhstan

Cited by 4 publications

References 32 publications

Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia

Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia

Recombinant Forms of HIV-1 in the Last Decade of the Epidemic in the Russian Federation

Genetic Diversity and Drug Resistance Mutations in HIV-1 pol Gene Sequences in the Philippines: A Retrospective Genomic Analysis

Contact Info

Product

Resources

About